Biomarkers to Guide the Timing of Aortic Valve Replacement in Asymptomatic Aortic Stenosis: Where Do We Stand After Early TAVR?

Jarett D. Berry; James A. de Lemos

doi:10.1161/circulationaha.125.075062

Biomarkers to Guide the Timing of Aortic Valve Replacement in Asymptomatic Aortic Stenosis: Where Do We Stand After Early TAVR?

J Jarett D. Berry (Department of Internal Medicine, University of Texas at Tyler School of Medicine, Tyler, TX (J.D.B.).) J James A. de Lemos (Division of Cardiology (J.A.H., J.d.L.), UT Southwestern Medical Center, Dallas, TX.)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Circulation

Volume / Issue Vol. 151, Issue 22

Published June 03, 2025

Pages 1565-1567

DOI 10.1161/circulationaha.125.075062

ISSN 0009-7322

Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (2)

J

Jarett D. Berry

Department of Internal Medicine, University of Texas at Tyler School of Medicine, Tyler, TX (J.D.B.).

J

James A. de Lemos

Division of Cardiology (J.A.H., J.d.L.), UT Southwestern Medical Center, Dallas, TX.

Biomarkers to Guide the Timing of Aortic Valve Replacement in Asymptomatic Aortic Stenosis: Where Do We Stand After Early TAVR?

Article Details

Journal Info

Authors (2)

Related Articles from this Journal

Occupational Radiation Safety in Electrophysiology During Pregnancy: Evaluating Uterine Radiation Doses During Catheter Ablations and Device Implantations

Response by Rogers et al to Letter Regarding, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”

Clinical Cardiology at the Crossroads: Perspectives on the Next Era at <i>Circulation</i>

ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction

Letter by Li et al Regarding Article, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”